Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Temsirolimus

FDA-approved product (solution, intravenous), marketed as Temsirolimus, Torisel.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Temsirolimus
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Clear cell renal carcinoma
  • Mantle cell lymphoma
  • Neoplasm
  • Renal cell carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Mammalian target of rapamycin (mtor) kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae, MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA70.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae46.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Temsirolimus in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Temsirolimus with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Rapamycin Use in Calcineurin Inhibitor (CNI)-Free Immunosuppression for Stabilization/Improvement of Renal Function After Heart Transplantation

    NCT00123331 · start 2003-10

    Registered record
    Registry ID
    NCT00123331
    Conditions
    Heart Transplantation; Renal Failure
    Interventions
    Cyclosporine discontinuation; Rapamycin medication
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-10
    Completion
    2005-04
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Transplantation; Renal Failure
    InterventionCyclosporine discontinuation; Rapamycin medication
    PhasePhase 4
    Registry statusCompleted

  • Islet Allotransplantation With Steroid Free Immunosuppression

    NCT00446264 · start 2003-05

    Registered record
    Registry ID
    NCT00446264
    Conditions
    Type 1 Diabetes; Hypoglycemia; Metabolic Diseases
    Interventions
    islet transplantation; daclizumab - sirolimus - tacrolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-05
    Completion
    2009-02
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 1 Diabetes; Hypoglycemia; Metabolic Diseases
    Interventionislet transplantation; daclizumab - sirolimus - tacrolimus
    PhasePhase 2
    Registry statusCompleted

  • CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma

    NCT00033267 · start 2002-04

    Registered record
    Registry ID
    NCT00033267
    Conditions
    Recurrent Mantle Cell Lymphoma
    Interventions
    temsirolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-04
    Completion
    2008-02
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Mantle Cell Lymphoma
    Interventiontemsirolimus
    PhasePhase 2
    Registry statusCompleted

  • Pre Transplant Rapamycin Treatment in Islet Transplantation Alone

    NCT01060605 · start 2001-10

    Registered record
    Registry ID
    NCT01060605
    Conditions
    Diabetes Mellitus, Type 1
    Interventions
    rapamycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-10
    Completion
    2009-09
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 1
    Interventionrapamycin
    PhasePhase 3
    Registry statusCompleted

  • Renal Function Optimization With Mycophenolate Mofetil (MMF) Immunosuppressor Regimes (ALHAMBRA)

    NCT00290069

    Registered record
    Registry ID
    NCT00290069
    Conditions
    Kidney Diseases; Graft Rejection
    Interventions
    Tacrolimus; Rapamycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    94

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Diseases; Graft Rejection
    InterventionTacrolimus; Rapamycin
    PhasePhase 4
    Registry statusUnknown